Monopar to Present at Roth Inaugural Healthcare Opportunities Conference

WILMETTE, Ill., Sept. 28, 2022 (GLOBE NEWSWIRE) -- Monopar Therapeutics Inc. (Nasdaq: MNPR), a clinical-stage biopharmaceutical company focused on developing proprietary therapeutics designed to extend life or improve the quality of life for cancer patients, today announced that Chandler Robinson, MD, Monopar’s Chief Executive Officer, will present at the Roth Inaugural Healthcare Opportunities Conference.

Presentation Details:

Date: October 6, 2022Time: 12:00 p.m. (ET)Location: The Yale Club, New York City, New York

https://www.roth.com/conferences/upcoming-conferences

About Monopar Therapeutics Inc.

Monopar Therapeutics is a clinical-stage biopharmaceutical company focused on developing proprietary therapeutics designed to extend life or improve the quality of life for cancer patients. Monopar's pipeline consists of Validive® for the prevention of chemoradiotherapy-induced severe oral mucositis in oropharyngeal cancer patients; camsirubicin for the treatment of advanced soft tissue sarcoma; a late-stage preclinical antibody, MNPR-101, for advanced cancers and severe COVID-19; and an early-stage camsirubicin analog, MNPR-202, for various cancers. For more information, visit: www.monopartx.com.

CONTACT:  

Monopar Therapeutics Inc. Investor Relations   Kim R. Tsuchimoto   Chief Financial Officer   [email protected]

Follow Monopar on social media for updates:  Twitter: @MonoparTx  LinkedIn: Monopar Therapeutics

 

Source: Monopar Therapeutics Inc.

---

Serious News for Serious Traders! Try StreetInsider.com Premium Free!

---

You May Also Be Interested In

• Captain James A. Lovell Federal Health Care Center to Treat Post-Traumatic Stress With Virtual Reality Donated by Nonprofit SoldierStrong
• Fashion Meets Wellness: Herbalife and FIFA 1904 Launch Immersive Fashion, Soccer and Wellness Experience in New York City’s SoHo
• eCapital Names Rosario Ingargiola as Chief Digital Assets Officer